Background: Systemic lupus erythematosus (SLE) is characterized by increased cardiovascular morbidity and mortality. SLE patients have increased prevalence of subclinical atherosclerosis, although the mechanisms of this observation remain unclear. Considering the emerging role of monocytes in atherosclerosis, we aimed to investigate the relationship between subclinical atherosclerosis, endothelial dysfunction and the phenotype of peripheral blood monocytes in SLE patients. Methods: We characterized the phenotype of monocyte subsets defined by the expression of CD14 and CD16 in 42 patients with SLE and 42 non-SLE controls. Using ultrasonography, intima-media thickness (IMT) of carotid arteries and brachial artery flowmediated dilation (FMD) as well as nitroglycerin-induced dilation (NMD) were assessed. Results: Patients with SLE had significantly, but only modestly, increased IMT when compared with non-SLE controls (median (25th/75th percentile) 0.65 (0.60/0.71) mm vs 0.60 (0.56/0.68) mm; p < 0.05). Importantly, in spite of early atherosclerotic complications in the studied SLE group, marked endothelial dysfunction was observed. CD14dimCD16þproinflammatory cell subpopulation was positively correlated with IMT in SLE patients. This phenomenon was not observed in control individuals. Interestingly, endothelial dysfunction assessed by FMD was not correlated with any of the studied monocyte subsets. Conclusions: Our observations suggest that CD14dimCD16þmonocytes are associated with subclinical atherosclerosis in SLE, although the mechanism appears to be independent of endothelial dysfunction. Lupus (2016) 25, 18-27.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by increased cardiovascular morbidity and mortality. 1 Already in the late 1970s it was noted that myocardial infarction (MI) and cardiovascular diseases were the most important causes of death in patients with SLE, even more than in other rheumatoid disease. 2 Indeed, the incidence of MI is more than 50 times higher in women with SLE than in healthy individuals. 3 This is a result of increased prevalence of atherosclerosis in SLE. [4] [5] [6] [7] While increase in subclinical atherosclerosis translates to increased cardiovascular risk, the mechanism of this observation in SLE remains unclear. Nevertheless, some studies demonstrated that atherosclerosis in SLE patients was only modestly increased or even absent. 8, 9 Recently, it has been postulated that systemic inflammation and the presence of autoantibodies against endothelial cell membrane antigens induces a proinflammatory phenotype of endothelium, resulting in endothelial dysfunction. 10, 11 While this is an interesting possibility, vascular disease appears to be a universal feature of SLE. This is already observed at early stages of the disease in patients with low disease activity and is not primarily associated with autoantibody-mediated damage. Therefore, it is very likely that a general inflammatory activation leads to initiation of endothelial dysfunction and atherosclerosis in SLE patients.
One of the prominent inflammatory features associated with SLE is the dysfunction of peripheral blood monocytes. 12 In particular, imbalance within the monocyte subsets defined by the expression of CD14 and CD16 antigens may be important. 13 Classical, quiescent monocytes are strongly positive for CD14 (lipopolysaccharide (LPS) receptor) but do not express Fc gamma receptor III CD16. In contrast, monocytes co-expressing CD16 and CD14 are proinflammatory and pro-atherogenic, although their nature varies depending on the level of CD14 expression. Cells with low expression of CD14, i.e. CD14dimCD16þ, represent a mature macrophagelike monocyte, being an important source of tumor necrosis factor alpha (TNF-alpha) while the role of CD14highCD16þ monocytes is less clear. CD14highCD16þ and CD14dimCD16þ may be associated with increased cardiovascular disease [14] [15] [16] as well as with myocardial dysfunction and recovery following MI, [17] [18] [19] although their relationship to subclinical atherosclerosis is less clearly defined. Interestingly, we have recently observed that CD14high monocytes are increased in patients with ankylosing spondylitis. 20 It has been demonstrated that CD14highCD16-, CD14highCD16þ and CD14dimCD16þ are differentially regulated in SLE, but the importance of this observation to cardiovascular risk and atherosclerosis remains unknown. 21 Therefore, it is very interesting to postulate that monocyte subpopulations in SLE are associated with the development of vascular disease. The aim of the present study was to evaluate the relationship between subclinical atherosclerosis assessed as intima-media thickness (IMT), endothelial dysfunction and the phenotype of peripheral blood monocytes in SLE patients.
Materials and methods

Patients and controls
Forty-two patients diagnosed with SLE (36 females (F)/six males (M); aged 44 AE 14, range 19-75 years) according to the American College of Rheumatology Criteria and 42 non-SLE controls (37 F/5 M; aged 41 AE 11, range 22-68 years) were included in the study. Average Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 22 was 8.02 AE 8.11. SLE patients were treated using typical immunosuppression schedules with prednisone, hydroxychloroquine/chloroquine, azathioprine, mycophenolate mofetil or cyclophosphamide. Participants were carefully screened for risk factors for atherosclerosis, defined as follows: hypercholesterolemia (total plasma cholesterol level > 5 mmol/l or treatment with statins); diabetes (fasting glucose level ! 7 mmol/l or HbA1c > 6.5% or current treatment with insulin or oral hypoglycemic agents); hypertension (!140/90 mmHg or treatment with antihypertensive agents), and smoking (current/ within last six months). Coronary artery disease (CAD) was defined by clinical history of CAD, particularly MI, angina, angioplasty, or coronary artery bypass grafting, previous angiography because of CAD or abnormal results of coronary angiography. Characteristics of patients with SLE and controls are shown in Table 1 . The control group was recruited from our general medical clinic from individuals attending regular health check-ups and was matched for age, sex and major risk factors including hypertension, diabetes, hypercholesterolemia, CAD, peripheral arterial disease (PAD), transient ischemic attack (TIA) and MI. As expected, nephritis and proteinuria were significantly more common in SLE patients. All participants gave written informed consent and the study was approved by the local ethics committee of the Jagiellonian University (KBET/28/B/2011).
Flow cytometry analysis of antigen expression on peripheral blood monocytes
Surface antigens were studied on peripheral blood mononuclear cells (PBMCs) as previously described. 20, 21 Briefly, PBMCs were isolated by gradient centrifugation using Lymphocyte Separation Medium (LSM) 1077 (PAA Laboratories GmbH, Austria) from ethylenediaminetetraacetic acid (EDTA)-treated blood. PBMCs were further suspended in phosphate-buffered saline (PBS) containing 1% heat-inactivated fetal bovine serum (FBS) (Gibco, Life Technologies, USA) and were used immediately after isolation. A total of 250,000 PBMCs were stained for 20 minutes with fluorochrome-conjugated monoclonal antibodies: anti-CD14-PerCP (MÈP9), anti-CD16-APC-H7 (3G8), anti-human leukocyte antigen (HLA)-DR-PE-Cy7 (L243) (BD, Pharmingen, CA, USA). After staining, cells were washed twice with PBS containing 1% FBS.
Cells were processed in the FACSVerse flow cytometer and analyzed using FlowJo software (TreeStar, USA). Monocytes were gated according to forward scatter (FSC) and side scatter (SSC) signals as described previously. 21 Subsequently, cells were gated in an HLA-DR/CD14 plot to exclude HLA-DR-negative natural killer cells. Finally, we analyzed cells for CD14 and CD16 expression, which allowed for discrimination of major monocyte subpopulations as described. 23 Absolute monocyte number/mm 3 was calculated. 20
Assessment of endothelial function
Endothelial function was assessed by flow-mediated dilation (FMD) measurement of the brachial artery diameter, before and after five-minute long brachial artery occlusion (using a sphygmomanometer cuff), as described previously. 5 Measurements were performed in a dimmed, temperature-controlled room using a Toshiba Xario Ultrasound System and an 8 MHz linear transducer. Nitroglycerine-mediated dilation (NMD) was measured to study non-endotheliumdependent vasodilation by assessing vessel diameter before use of nitroglycerine (Nitromint, aerosol, 400 mg s.l.) and one, two and five minutes after sublingual nitroglycerin application. 5 Images were digitally recorded and analyzed using ImagePro Plus software.
Measurement of carotid artery IMT
IMT measurements were taken in accordance with commonly used standard methods 5 at 12 different points (2 cm below common carotid artery sinuses, ca. every 1 cm, omitting visible carotid plaques), on the right and left common carotid arteries. The distance from the border between the artery lumen and carotid artery intima and second bright m-line (border between media and adventitia) was measured. 5 Images were digitally recorded and analyzed using ImagePro Plus. Mean and maximal IMT were calculated (IMTmean and IMTmax, respectively).
Statistical analysis
Analysis was performed using StatSoft Statistica software or IBM SPSS Statistics. Compliance in the distribution of variables with normal distribution was verified using the Shapiro-Wilk test. Data are presented as means AE SD. Differences of means were compared among groups by two-way analysis of variance (ANOVA) and Bonferroni's post-hoc test. When appropriate, Student's t-test was used and considered significant when p < 0.05. Nonnormally distributed variables were analyzed using non-parametric Mann-Whitney U test and are presented as median (10th-90th percentile).
Analysis of correlations between FMD, NMD, IMT, was performed using Spearman test.
Results
SLE patients exhibit higher IMT and impaired endothelial function
Studied patients with SLE have a higher IMT when compared to healthy individuals (median (25th/75th percentile) 0.65 (0.60/0.71) mm vs 0.60 (0.56/0.68) mm; p < 0.05, Figure 1(a) ). Similarly, maximal IMT was 0.76 (0.70/0.79) mm in SLE patients vs 0.68 (0.63/0.78) mm in healthy individuals, p < 0.01 (Figure 1(b) ). These values were only modestly increased and did not reach the range generally considered pathological ( > 0.9 mm), indicating that we assessed patients at an early stage of carotid atherosclerosis. SLE patients exhibited impaired FMD in comparison to healthy individuals (median (25th/ 75th percentile) 9.71% (6.27/11.20) vs 13.50% (11.85/15.88); p < 0.01, Figure 1(c) ), representing the presence of a significant degree of endothelial dysfunction in SLE. At the same time, NMD did not differ between healthy participants and SLE patients (Figure 1(d) ).
Monocytes from SLE patients exhibit a higher percentage of CD14highCD16þ cells
No significant differences were observed in the number of total peripheral blood monocytes between patients with SLE and healthy participants (426 AE 212 cells/mm 3 vs 396 AE 137 cells/mm 3 ). Peripheral blood monocytes after labeling with monoclonal anti-CD14 and anti-CD16 antibodies can be separated into three functionally distinct subpopulations: CD14highCD16-, CD14highCD16þ and CD14dimCD16þ. We compared the content of individual monocyte subpopulations between groups of patients and control participants. SLE was associated with an increased percentage of CD14highCD16þ monocytes when compared to healthy individuals (8.81 AE 4.24% vs 4.89 AE 1.51%, p < 0.01). Similarly, the absolute number of these cells was increased (37 AE 24 cells/ mm 3 vs 19 AE 8 cells/mm 3 , p < 0.01, Table 2 ). At the same time, the percentage of classical, nonactivated CD14highCD16-monocytes was slightly decreased in SLE (86 AE 5.5% vs 89.1 AE 2.55%, p < 0.01), while this difference was not sufficient to reach statistical significance when calculated per mm 3 . No significant difference was observed in either the percentage or absolute number of CD14dimCD16þ between SLE patients and control subjects ( Table 2) .
Correlations of monocyte subsets with subclinical atherosclerosis in SLE patients
We next assessed the relationships between monocyte subsets (CD14highCD16-, CD14highCD16þ and CD14dimCD16þ) and IMT in SLE patients and controls. The percentage and the absolute number/mm 3 of CD14dimCD16þ monocytes in SLE patients positively correlated with IMT (r ¼ 0.33, p ¼ 0.03; Figure 2 ), while other subpopulations did not display a significant relationship. This phenomenon was not observed in non-SLE controls, suggesting that CD14dimCD16þ monocytes may be specifically associated with the risk of atherosclerosis in patients with SLE. The studied population was too small for detecting sufficient effects in multivariate analysis. Type III sum of squares ANOVA has shown that after taking into account other possible predictors of IMT (smoking, hypertension, diabetes and hypercholesterolemia), only diabetes remained independently associated with IMT in this group and CD14dimCD16þ cells showed borderline association (p ¼ 0.1).
Relationships between monocyte subsets and endothelial dysfunction
As endothelial dysfunction is an important mechanism of atherosclerosis, and is observed in SLE, we next analyzed the relationships between individual monocyte subpopulations and FMD as well as nitroglycerin-induced (nonendothelium dependent) dilation. We did not observe significant correlations between monocyte subsets (CD14highCD16-, CD14highCD16þ, CD14dimCD16þ) and FMD or NMD in either the SLE patients or the non-SLE controls (Figure 3 ).
Discussion
Patients with SLE have a considerable risk for premature death due to coronary heart disease and accelerated atherosclerosis, 6,24,25 although some investigators have not shown accelerated atherosclerosis, 9 while many studies show only modest increase. 8 Thus, the mechanisms of this increased risk remain unclear, although recent interest has focused on the importance of immune mechanisms of atherosclerosis and cardiovascular disease, which is particularly relevant to SLE in which immune dysfunction is of primary importance. 26 However, the exact nature of increased susceptibility to atherosclerosis in SLE is not currently known. 6, 25 In the studied population, with a relatively early stage of subclinical atherosclerosis (judged by IMT < 0.9 mm), we confirmed that SLE was associated with modestly increased carotid IMT when compared to controls. This is consistent with previous reports, 7, 25 although in the present study we observed only a modest increase in atherosclerosis, which may be related to the comparatively young age of the studied patients. At the same time, we have observed that patients with SLE have strongly impaired FMD in response to reactive hyperemia in comparison to age-and sex-matched non-SLE individuals, and is particularly blunted in individuals with a high SLEDAI score (data not shown). This is consistent with previous data. 25, 27, 28 El-Magadmi et al. have also shown that endothelial dysfunction in SLE patients correlated negatively with IMT and that endothelial dysfunction remained a significant predictor of IMT even after adjustment for other classic coronary heart disease risk factors. 29 We have shown that NMD was not reduced in SLE patients, which is in line with other studies. 27 Impaired FMD with preserved NMD suggests endothelial cell pathology with vascular smooth muscle reactivity. Importantly, FMD is considered to be a good predictor of cardiovascular complications in lupus patients, but the reduction of FMD does not correlate with the extent of atherosclerotic 27 Previous studies have demonstrated that FMD decreases with increasing age and is impaired in people with hypertension, obesity, type 2 diabetes mellitus, hypercholesterolemia and in chronic smokers. 30 The incidence of hypertension and other risk factors in our study is comparable between SLE patients and the control group to exclude the potential influence of those factors that can affect FMD. Moreover, it is important to note that our study was not designed or powered to compare incidence of hypertension or major risk factors/comorbidities in SLE and the general population. Karadag et al. examined novel cardiovascular risk factors and cardiac event predictors in inactive SLE patients who did not have major cardiovascular risk factors. They found higher levels of high-sensitivity C-reactive protein (hs-CRP) and lower FMD in SLE patients when compared with the control group, suggesting that SLE patients without traditional major cardiovascular risk factors may have an increased risk of cardiovascular disease. 31 The mechanisms of increased susceptibility for atherosclerosis are complex in SLE and not fully recognized. These may include an autoimmune reaction with the generation of autoantibodies, overproduction of pathogenic cytokines or formation of immune complexes.
Recent data indicate that imbalances of monocyte subsets may be related to increased risk of cardiovascular complications in patients with acute coronary syndromes or CAD. 32 Indeed, monocyte subsets are affected by SLE, but little is known about how these changes in monocyte phenotype may be related to subclinical atherosclerosis or endothelial dysfunction observed in SLE patients. Chronic inflammation is closely linked to endothelial dysfunction, activation of immune cells and their subsequent migration into intima and sub-intimal layers of the vessel wall. 33 Peripheral blood monocytes constitute a heterogeneous group of cells with subpopulations characterized by high proinflammatory potential (CD14dim CD16þ), a more quiescent phenotype (CD14highCD16-) and an intermediate phenotype (CD14highCD16+). 21, 34 Imbalances between these subpopulations have been defined in various disease states including bacterial infections, rheumatoid arthritis, SLE and atherosclerosis. 35 Peripheral blood monocytes phenotype and functions may also change in relation to aging, 36, 37 chronic inflammatory conditions or obesity. 35, 38 Increased number of CD16þ monocytes was associated with cardiovascular disease and with the development of atherosclerosis. 16 The relationship between the frequency of CD16þ monocytes and IMT as the marker of subclinical atherosclerosis was shown in patients with high cardiovascular risk suffering from chronic kidney disease (CDK). 14, 39 Recently, it has been described that CD16þ monocytes were significantly associated with obesity, IMT and subclinical atherosclerosis in low-risk individuals. 38 CD16þ monocytes can be divided into CD14dim and CD14high cells, which display distinct phenotypic and functional properties. 34 The pathogenic role of these monocyte subsets in autoimmune disease and increased cardiovascular risk due to accelerated atherosclerosis is not fully understood.
In the present study, we observed that patients with SLE have both a higher percentage and absolute number of CD14highCD16þ monocytes when compared to controls, which is interesting, as increased number of CD14highCD16þ monocytes is associated with cardiovascular events and death in a high-risk population of dialysis patients 14 as well as in a population of non-dialysis patients with CDK. 39 Additional subgroups analysis between patients with nephritis and individuals without renal disturbances revealed no significant differences in the percentage of monocyte subsets in our study population. However, the limitation of this study is a relatively small group of patients with nephritis. CD14highCD16þ monocytes are correlated with the number of risk factors for atherosclerosis in patients with CAD. 32 On the other hand, increased levels of proinflammatory CD14dimCD16þ monocytes were observed in patients with CAD when compared to controls. 16 Interestingly, increased subsets of CD14dimCD16þ cells were related to coronary plaque vulnerability in patients with stable angina pectoris. 40 Rogacev et al. demonstrated that CD14dimCD16þ monocytes were significantly associated with body mass index (BMI) and showed correlation with traditional cardiovascular risk factors, whereas CD14highCD16-and CD14highCD16þ cells did not. 38 Proinflammatory CD14dimCD16þ monocytes correlate with IMT in renal transplant recipients and are independently associated with subclinical atherosclerosis in these patients. 41 In our study, we observed that both the percentage and absolute number of CD14dimCD16þ monocytes in SLE patients, but not in controls, positively correlated with subclinical atherosclerosis measured as IMT. At the same time, we have observed no relationship between FMD and any of the three distinct subsets of monocytes including CD14highCD16-, CD14highCD16þ and CD14dimCD16þ in neither SLE patients nor in controls. This suggests that pro-atherosclerotic properties of CD14dim cells may provide an additional mechanism for increased atherosclerosis susceptibility, which is independent of endothelial dysfunction.
CD14dimCD16þ monocytes have also been previously shown to positively correlate with serum cholesterol and triglyceride levels in patients with hypercholesterolemia. 42 Interestingly, Mosig et al. demonstrated that CD14dimCD16þ monocytes from patients with familial hypercholesterolemia preferentially exhibit increased uptake of oxidized low-density lipoprotein (LDL) via CD36 and a higher adherence to activated endothelial cells in response to oxidized LDL and native LDL stimulation. 43 This observation supports the previous finding that CD14dimCD16þ monocytes show potent capacity to invade vascular lesions. CD16þ monocytes are also considered to have a more mature phenotype when compared to CD16-and exhibit features of tissue macrophages. 44 CD14dimCD16þ monocytes have a proinflammatory phenotype and they are the main producers of TNF-a in human blood, whereas the anti-inflammatory interleukin-10 (IL-10) is low or absent in these cells. 45 This is consistent with other observations that the serum concentrations of TNF-a were elevated in subjects with the highest quartiles of CD14dimCD16þ monocytes. 16 This provides several direct mechanisms through which CD14dimCD16þ could be involved in the development of human atherosclerosis. 38, 39 It is likely elevated production of proinflammatory cytokines such as TNF-a in SLE 46 is associated with increased IMT and possibly faster progression for atherosclerosis. This could explain why we observed association only in SLE patients but not in the control population. It is also possible that CD14dimCD16þ monocytes work in concert with other pathophysiological mediators in SLE that are not present in controls to promote IMT.
In summary, our study shows that CD16þCD14dim monocytes may be an important subpopulation of proinflammatory monocytes related to increased development of atherosclerosis in SLE. While this is interesting, no clear relationship was found between these cells and endothelial dysfunction. This could suggest that proinflammatory effects of these monocytes on the vascular wall are independent of nitric oxide-dependent endothelial dysfunction and could be an important treatment target. 47, 48 This could include direct interactions with other vascular cells. 42 Future mechanistic studies in SLE patients are necessary to further elucidate the mechanism of this observation.
